优化血压控制:一种随机比较试验的洛萨坦/Chlorthalidone与洛萨坦/Hydrochlorothiazide
Isabel E Rucker-Joerg1, Ernesto G Cardona-Muñoz2, Francisco G Padilla-Padilla3
1Clinical Research Institute, Blvrd. Manuel Avila Camacho #1994, San Lucas Tepetlacalco, Tlalnepantla, Estado de Mexico, Mexico.
Cardiology and therapy
|April 24, 2025
概括
洛萨坦/甲联合治疗有效降低了高血压患者的血压. 这种组合在实现腹压血压目标方面表现出更大的有效性,与具有类似安全性概况的洛萨坦/基化物相比.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 高血压是心血管疾病的主要危险因素,是全球死亡的主要原因.
- 低血压控制率通常与单一治疗有关.
- 临床指南建议使用组合疗法,以改善高血压管理.
研究的目的:
- 为了比较洛萨坦/chlorthalidone (L/C) 与洛萨坦/水 thiazide (L/H) 在降低血压方面的疗效.
- 评估在接受组合治疗的高血压患者中达到目标血压水平的程度.
主要方法:
- 一个随机,双盲,前性的多中心临床试验.
- 患者被分配到L/C或L/H,如果目标血压没有达到,则剂量升级.
- 血压在30天和60天后进行监测.
主要成果:
- 无论是L/C还是L/H,都显著降低了心压和腹压血压.
- L/C 组表现出更大程度的减轻腹压血压,并更有可能实现血压目标.
- 在两组治疗中,不良事件是相似的和轻微的.
结论:
- 洛萨坦/chlorthalidone和洛萨坦/基亚胺是有效的抗高血压组合.
- 洛萨坦/克洛塔利在降低腹压血压和实现治疗目标方面表现出更高的疗效.
- 两种组合疗法都表现出有利的和相似的安全性.
相关概念视频
Antihypertensive Drugs: Thiazide-Class Diuretics
479
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
479
Antihypertensive Drugs: Potassium-Sparing Diuretics
424
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
424
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
430
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
430
Antihypertensive Drugs: Angiotensin II Receptor Blockers
560
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
560
Antihypertensive Drugs: Direct Renin Inhibitors
466
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354


